Gilead Sciences Inc. will license an early-stage inhalable drug from MicroDose Therapeutx Inc. that is aimed at respiratory syncytial virus.
Foster City-based Gilead (NASDAQ: GILD) and MicroDose of Monmouth Junction, N.J., did not disclose specific financial terms of the deal. MicroDose will receive an upfront payment and Gilead will provide research funding supporting the drug, MDT-637, through Phase IIa clinical trials.
No comments:
Post a Comment